Impact of transforming growth factor beta 1 on normal and thyroid cancer side population cells.
Side population cells
TGF-β
Thyroid
Thyroid cancer
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
14
09
2021
accepted:
19
01
2022
pubmed:
5
2
2022
medline:
7
5
2022
entrez:
4
2
2022
Statut:
ppublish
Résumé
To determine the impact of exogenous transforming growth factor beta 1 (TGF-β1) on side population (SP) cells isolated from normal, papillary thyroid cancer and anaplastic thyroid cancer cell lines and from human thyroid tissues. All cell populations were stained with Hoechst 33342 and analysed using dual wavelength flow cytometry to identify SP cells. This SP assay was used to assess the impact of TGF-β1 treatment and withdrawal of treatment on SP percentages. Semi-quantitative and quantitative PCR were used for molecular analysis of cells pre and post TGF-β1 treatment. All cell lines expressed mRNA for both TGFB1 and its receptors, as well as showing variable expression of CDH1 and CDH2, with expressing of CDH1 being highest and CDH2 being lowest in the normal cell line. Exposure to exogenous TGF-β1 resulted in a reduction in mRNA expression of ABCG2 compared to controls which was significant between control and treated cancer cell lines. SP cells were isolated from primary human thyroid tissues, with numbers being significantly higher in papillary thyroid cancers. Exposure to TGF-β1 decreased the SP percentage in both thyroid cancer cell lines and completely abrogated these cells in the primary papillary thyroid cancer cultures. On withdrawal of TGF-β1 the SP phenotype was restored in the cancer cell lines and SP percentages increased to above that of untreated cells. TGF-β1 exposure transiently regulates thyroid cancer SP cells, leading to a reduction in SP percentages, while withdrawal of TGF-β1 results in restoration of the SP phenotype.
Identifiants
pubmed: 35118633
doi: 10.1007/s12020-022-02990-4
pii: 10.1007/s12020-022-02990-4
pmc: PMC9068642
doi:
Substances chimiques
RNA, Messenger
0
Transforming Growth Factor beta
0
Transforming Growth Factor beta1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
359-368Informations de copyright
© 2022. The Author(s).
Références
Mol Cancer Ther. 2011 Feb;10(2):325-35
pubmed: 21216927
Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2803-8
pubmed: 17296934
Endocr Pathol. 2013 Dec;24(4):206-12
pubmed: 24126800
Front Cell Dev Biol. 2020 Jul 08;8:605
pubmed: 32733895
Stem Cell Rev Rep. 2013 Oct;9(5):731-9
pubmed: 23619929
J Clin Endocrinol Metab. 2011 May;96(5):E772-81
pubmed: 21389145
J Otolaryngol Head Neck Surg. 2014 Jul 18;43:22
pubmed: 25927212
Exp Cell Res. 2006 Nov 15;312(19):3701-10
pubmed: 17046749
Mol Med. 2012 Oct 24;18:1197-208
pubmed: 22801793
Cancer Lett. 2012 Oct 1;323(1):97-105
pubmed: 22521545
Cells. 2019 Sep 20;8(10):
pubmed: 31547193
Curr Opin Oncol. 2013 Jan;25(1):76-84
pubmed: 23197193
Blood. 2002 Jan 15;99(2):507-12
pubmed: 11781231
Cancer Res. 2008 Feb 1;68(3):800-7
pubmed: 18245481
Dev Biol. 2004 Jan 1;265(1):262-75
pubmed: 14697368
J Clin Endocrinol Metab. 2007 Sep;92(9):3681-8
pubmed: 17609303
Exp Cell Res. 2019 Jan 1;374(1):104-113
pubmed: 30465733
Int J Oncol. 2017 May;50(5):1567-1578
pubmed: 28393241
Am J Pathol. 2007 Sep;171(3):1037-46
pubmed: 17724139
Int J Oncol. 2013 Jul;43(1):113-20
pubmed: 23604232
Endocrinology. 2007 Apr;148(4):1797-803
pubmed: 17234707
Tumour Biol. 2014 Oct;35(10):9879-92
pubmed: 24993095
Transl Oncol. 2020 Nov;13(11):100845
pubmed: 32781367
ISRN Mol Biol. 2012 Dec 24;2012:381428
pubmed: 27340590
Stem Cells. 2005 Sep;23(8):1059-65
pubmed: 16002779
Cancer. 1994 Apr 15;73(8):2206-12
pubmed: 8156527
Int J Cancer. 2009 Jun 15;124(12):2771-9
pubmed: 19296540
Hum Pathol. 2017 Sep;67:11-17
pubmed: 28411177
Front Endocrinol (Lausanne). 2012 Nov 16;3:133
pubmed: 23162534
World J Surg. 2018 Feb;42(2):350-357
pubmed: 29167950